enGene Therapeutics Inc.
ENGN
$1.70
$0.010.59%
NASDAQ
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.83M | 30.98M | 28.69M | 27.11M | 24.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 132.58M | 127.74M | 123.17M | 101.14M | 87.95M |
| Operating Income | -132.58M | -127.74M | -123.17M | -101.14M | -87.95M |
| Income Before Tax | -127.11M | -122.46M | -117.30M | -94.21M | -79.63M |
| Income Tax Expenses | -258.00K | -18.00K | 0.00 | 516.00K | 248.00K |
| Earnings from Continuing Operations | -126.85 | -122.44 | -117.30 | -94.72 | -79.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -126.85M | -122.44M | -117.30M | -94.72M | -79.88M |
| EBIT | -132.58M | -127.74M | -123.17M | -101.14M | -87.95M |
| EBITDA | -131.91M | -127.14M | -122.66M | -100.72M | -87.58M |
| EPS Basic | -2.18 | -2.25 | -2.29 | -1.90 | -1.65 |
| Normalized Basic EPS | -1.36 | -1.40 | -1.43 | -1.18 | -1.03 |
| EPS Diluted | -2.18 | -2.25 | -2.29 | -1.90 | -1.65 |
| Normalized Diluted EPS | -1.36 | -1.40 | -1.43 | -1.18 | -1.03 |
| Average Basic Shares Outstanding | 239.47M | 220.76M | 204.48M | 197.53M | 190.60M |
| Average Diluted Shares Outstanding | 239.47M | 220.76M | 204.48M | 197.53M | 190.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |